Identification of Serious Drug–Drug Interactions: Results of the Partnership to Prevent Drug–Drug Interactions

Malone, Daniel C.; Abarca, Jacob; Hansten, Philip D.; Grizzle, Amy J.; Armstrong, Edward P.; Bergen, Robin C. Van; Duncan-Edgar, Babette S.; Solomon, Steven L.; Lipton, Richard B.

doi:10.1331/154434504773062591

Cited by 151 publications

(62 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Second, three different sources were used to identify DIs. Many studies have shown discrepancies in listing and rating systems between different DI sources [23,24,25,26]. The three sources selected - even if they are renowned and widely used worldwide [23,26,31] - are no exception to the rule.…”

Section: Discussionmentioning

confidence: 99%

“…First, most studies were retrospective in nature. Second, none of them used more than one source of information to detect DIs, although there is good evidence that no single source has sufficient sensitivity to detect DIs [23,24,25,26,27]. Third, previous studies did not take into account interactions with complementary or alternative medications, herbs or food.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Potential Interactions with Anticancer Agents: A Cross-Sectional Study

Mouzon¹,

Kerger²,

D’Hondt³

et al. 2013

Chemotherapy

View full text Add to dashboard Cite

Background: Patients with cancer are particularly susceptible to drug interactions (DIs), but the extent of the problem has received limited attention. We aimed to evaluate the frequency of interactions with anticancer agents in a group of cancer patients. Methods: The study was performed in a Belgian teaching hospital. One hundred and twenty-two patients with solid malignancies were included. A comprehensive drug history was performed by a clinical pharmacist. Three renowned DI compendia were used to identify DIs. Results: Forty-one potential interactions involving an anticancer agent and considered to be clinically significant were identified among 25% of patients. The anticancer drugs mostly involved were cisplatin and methotrexate, and the most frequent co-medications involved were vitamin K antagonists, proton pump inhibitors and diuretics. In the majority of cases, the potential adverse consequence was increased toxicity of the anticancer agent and/or of the co-medication. Less than 10% of DIs were identified by the three compendia. Conclusions: Preventive measures should be taken to avoid increased toxicity or decreased efficacy of the drugs. Most of the time, this simply involves surveillance of biological or clinical parameters. Collaboration with a clinical pharmacist may be useful for the prescribing physician.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Potential Interactions with Anticancer Agents: A Cross-Sectional Study

Mouzon¹,

Kerger²,

D’Hondt³

et al. 2013

Chemotherapy

View full text Add to dashboard Cite

show abstract

“…As part of the protocol, a list of clinically important drug-drug interactions in the elderly is developed by modifying Malone's and Hanlon's lists and adding four new drug-drug interactions [35,36]. A clinically based approach was used to build the protocol.…”

Section: The New Comprehensive Protocolmentioning

confidence: 99%

“…A list of 25 Delphi method-based drug-drug interactions with the greatest clinical importance in the general population was developed by Malone and colleagues in 2004 [35]. It was an important expert-based attempt to assess the clinical importance of drug interactions.…”

Section: The New Comprehensive Protocolmentioning

confidence: 99%

“…In order to extend the evaluation of prescribing quality, we included the adjusted Malone's and Hanlon's lists of potentially serious drug-drug interactions in the new screening tool (Table 5) [35,36]. As Malone's list focuses on the general population, we excluded drugs never or rarely prescribed in the elderly (e.g, oral contraceptives, zidovudine, or dexfenfluramine).…”

Section: The New Comprehensive Protocolmentioning

confidence: 99%

See 1 more Smart Citation

Potentially inappropriate medications in the elderly: a comprehensive protocol

Matanović

Vlahović‐Palčevski

2012

Eur J Clin Pharmacol

View full text Add to dashboard Cite

Elderly patients are at increased risk of drug-related morbidity and mortality. Avoiding the use of potentially inappropriate medications (PIMs) is one of the strategies that has been widely adopted to reduce the harmful consequences of drug use. There are several PIM screening tools available. In this review, we provide an overview of existing screening tools to detect PIMs in the elderly, emphasizing the advantages and disadvantages of each. Combining previously published and adopted tools (adjusted Beers list, French consensus panel, McLeod's list, and Lindblad's list of clinically important drug-disease interactions), we develop a new comprehensive tool that also includes the adjusted Hanlon's and Malone's lists of potentially serious drug-drug interactions in the elderly. In addition to listed PIMs and clinically important drug-drug interactions, alternative therapeutic solutions are suggested. The new protocol differentiates: drugs with an unfavorable benefit/risk ratio (to be avoided regardless of the underlying disease/condition), drugs with a questionable efficacy, and drugs to be avoided with certain diseases/conditions, and provides a list of potentially serious drug-drug interactions. A tool consisting of PIMs and potential drug-drug interactions within the same protocol provides more comprehensive quality assessment of drug-prescribing behavior to the elderly, which in turn may lead to better prescribing practices.

show abstract